You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤中異動 | 藥明生物盤中大漲8%,報於61.6港元
uSMART盈立智投 06-06 10:55

2022年6月6日10時55分,藥明生物(HK02269)盤中大漲8%,報於61.6港元,成交額達7.52億港元,換手率達到0.27%。

6月1日訊,騰盛博藥(02137)盤前高開6.65%,報8.98港元,盤前成交額719萬港元。集團公佈,旗下控股公司騰盛華創醫藥技術(北京)有限公司在北京市藥品監督管理局對騰盛華創及其受託生產方,無錫藥明生物技術股份有限公司和上海藥明生物技術有限公司,針對新冠中和抗體安巴韋單抗注射液和羅米司韋單抗注射液的原液和製劑生產車間開展生產質量管理規範(GMP)符合性檢查後,獲得其出具的正式檢查結論。結論表明,安巴韋單抗注射液和羅米司韋單抗注射液的生產基本符合《藥品生產質量管理規範(2010年修訂)》及其附錄要求,公司需進一步做好風險控制、並在與委託生產方合作完成具體整改要求後,啓動安巴韋單抗和羅米司韋單抗聯合療法的商業化生產及銷售。GMP符合性檢查的完成是安巴韋單抗和羅米司韋單抗聯合療法開始商業銷售前的最後一項監管要求。公司將與相關政府機構協商,並與其他合作方一起研究如何儘快讓中國患者獲益。公告指,安巴韋單抗和羅米司韋單抗聯合療法是中國首個自主研發並經過國際多中心大樣本隨機、雙盲、安慰劑對照研究證明有效的抗新冠病毒藥物。

5月24日,瑞銀:維持藥明生物(02269)“買入”評級,目標價110.67港元。4月14日,廣發證券:予藥明生物(02269)“買入”評級,目標價101.11港元。

最新的財務數據顯示,公司於2021年4季度,營業收入102.9億人民幣,淨利潤35.09億人民幣;營業收入同比增加83.35%,毛利潤同比增加90.05%,淨利潤同比增加107.28%。

盈立趨勢長盈模型最近一次交易信號,2022年6月2日出現關注信號,觸發價格爲57.0港元(信號僅供參考)。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account